CagriSema in 2026: Phase 3 status and evidence

Start with the combination

CagriSema is a fixed-dose combination of cagrilintide and semaglutide. The name does not make it interchangeable with either component alone, and a result for the combination does not become a result for one component.

What changed in September 2026

Novo Nordisk reported topline Phase 3 results from REIMAGINE 5 and REDEFINE 9 on 21 September 2026. The announcement describes CagriSema as investigational. A company topline release can identify the trial and reported endpoint, but it is not the same as a regulator's authorisation decision.

Read the trial before comparing it

Check the study population, comparator, duration, endpoint and analysis population. REIMAGINE and REDEFINE answer different research questions. A percentage from one programme should not be used as a universal outcome or as a direct ranking against a separate molecule.

Keep status and catalogue claims separate

The clinical-development status of CagriSema does not establish the composition, quality or authorised status of an online product using a related name. This guide offers no dosing, preparation or personal-use instructions.

Primary sources

• Novo Nordisk: 21 September 2026 CagriSema Phase 3 update
• Novo Nordisk: Q2 2026 CagriSema programme overview